Navigation Links
Study: Higher Hepatitis C Infection During Acupuncture in Asian Americans; polyDNA Recommends That Doctors Prescribe Gene-Eden-VIR against HCV

Rochester, NY (PRWEB) December 04, 2013

Acupuncture is one of the greatest risk factor among Asians for acquiring a Hepatitis C (HCV) infection. Results of a study “con?rmed ?ndings from prior cross-sectional studies of patients with chronic hepatitis C and similarly suggested that certain non-traditional risk factors such as acupuncture or exposure to contaminated needles are probable causes of HCV infection. In addition, acupuncture or exposure to dirty needles is a strong independent predictor of positive anti-HCV test results in Asians (1).”

Part of the reason acupuncture is a higher risk factor among Asian Americans than among other population groups is due to the role acupuncture plays in traditional Asian communities. Researchers found that “the difference in risk factors between Asian and non-Asian HCV patients could be due to … exposure to contaminated needles, since these tend to occur in more routine and casual settings in Asian communities (1).”

This is alarming since researchers showed in a study that Asians have a much higher risk of liver cancer than other ethnicities if they are infected with HCV. As study authors wrote, “Asian patients with chronic hepatitis C and cirrhosis have four times the risk of liver cancer compared to Caucasians, and twice the risk compared to non-Hispanic African Americans (1).”

In addition, the prevalence of HCV in Asian Americans is much higher than the national average. In fact, studies have shown that up to 6% of Asian Americans have HCV (1). “Preliminary studies from New York, Texas, Virginia, and California…have suggested a prevalence range from 2.2 - 6% in Asian Americans. This prevalence range is much higher than the national prevalence of 1.3% found in the National Health and Nutritional Examination Survey… (1).”

“We recommend that Asian Americans take Gene-Eden-VIR, a natural remedy designed to help the immune system target the latent HCV.” – Mike Evans, polYDNA

A study published on August 12, 2013 in the peer reviewed, medical journal
Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs, showed that Gene-Eden-VIR reduced HCV symptoms. Study authors wrote that, “Individuals infected with the hepatitis C virus…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR (2).” The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms (2).”

To learn more about Gene-Eden-VIR, and HCV visit All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.


(1) Less-established risk factors are common in asian americans with hepatitis C virus: a case-controlled study. Published in November 2013.

(2) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published August 12, 2013.

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
2. Nature Materials study: Graphene invisible to water
3. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
4. Nature Materials study: Boosting heat transfer with nanoglue
5. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
6. Study: Brain Imaging After Mild Head Injury/Concussion Can Show Lesions
7. New Study: Valtrex (Valacyclovir) Side Effects Target the Brain; polyDNA Suggests a Natural Herpes Remedy
8. Study: FOLFIRINOX Followed by Chemoradiation Shows Substantial Activity in Locally Advanced Pancreatic Cancer
9. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
10. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
11. California Biomedical Companies Report Higher Product Approvals, Fewer Delays
Post Your Comments:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
(Date:11/24/2015)... FAR HILLS, N.J. (PRWEB) , ... November 24, 2015 , ... ... University, as the recipient of the 2016 USGA Green Section Award. Presented annually since ... of golf through his or her work with turfgrass. , Clarke, of ...
(Date:11/24/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that ... and invited investors to participate via webcast. ... 1, 2015 at 11.00 a.m. Eastern Time --> ... 1, 2015 at 11.00 a.m. Eastern Time --> ... NY      Tuesday, December 1, 2015 at 11.00 ...
Breaking Biology Technology:
(Date:11/20/2015)... Connecticut , November 20, 2015 ... authentication company focused on the growing mobile commerce market ... CEO, Gino Pereira , was recently interviewed on ... interview will air on this weekend on Bloomberg ... Latin America . --> NXTD ) ("NXT-ID" ...
(Date:11/19/2015)... Nov. 19, 2015  Based on its in-depth analysis ... recognizes BIO-key with the 2015 Global Frost & Sullivan ... & Sullivan presents this award to the company that ... the needs of the market it serves. The award ... and expands on customer base demands, the overall impact ...
(Date:11/19/2015)... , Nov. 19, 2015  Although some 350 ... is dominated by a few companies, according to Kalorama ... own 51% of the market share of the 6.1 ... The World Market for Molecular Diagnostic s . ... "The market is still controlled by one company and ...
Breaking Biology News(10 mins):